In a recent bid Flexion Therapeutics Inc. [FLXN] faced a contemporary bid of $13.06 yielding a 28.04% incline where 1.75 million shares have exchanged hands over the last week. FLXN amount got a boost by 13.86% or $1.59 versus $11.47 at the end of the prior session. This change led market cap to move at 637.59M, putting the price 160.68% below the 52-week high and -43.17% above the 52-week low. The company’s stock has a normal trading capacity of 1.75 million shares while the relative volume is 3.08.

On 13, October 2020, Flexion Therapeutics Announces Preliminary Third-Quarter 2020 ZILRETTA® Net Sales of Approximately $23.6 Million. According to news published on Yahoo Finance, Company to hold conference call today at 8:30 a.m. ET.

Analyst Birdseye View:

The most recent analyst activity for Flexion Therapeutics Inc. [NASDAQ:FLXN] stock was on July 31, 2020, when it was Initiated with an Outperform rating from Oppenheimer, which also raised its 12-month price target on the stock to $19. Before that, on August 20, 2020, Goldman Recapitulated a Neutral rating and elevated its amount target to $15. On July 29, 2020, Credit Suisse Initiated an Outperform rating and boosted its price target on this stock to $19. On June 25, 2020, H.C. Wainwright Initiated a Buy rating and increased its price target to $25. On May 27, 2020, Guggenheim Initiated a Buy rating and increased its price target to $20. On December 27, 2019, The Benchmark Company Reiterated a Buy rating and boosted its amount target on this stock to $25. On December 05, 2019, Craig Hallum Initiated a Buy rating. On November 25, 2019 BTIG Research Initiated a Buy rating and elevated its amount target to $27.

In the past 52 weeks of trading, this stock has oscillated between a low of $5.01 and a peak of $22.98. Right now, the middling Wall Street analyst 12-month amount mark is $19.00. At the most recent market close, shares of Flexion Therapeutics Inc. [NASDAQ:FLXN] were valued at $13.06.


Flexion Therapeutics Inc. [NASDAQ:FLXN] most recently reported quarterly sales of 15.45 billion, which represented growth of -8.80%. This publicly-traded organization’s revenue is $253,323 per employee, while its income is -$520,045 per employee. This company’s Gross Margin is currently 82.00%, its Pretax Margin is -205.29, and its Net Margin is -205.29. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -58.36, -332.94, -60.43 and -68.13 respectively.

The Principal structure of this organization shows its whole liability to whole principal at 111.02 and the whole liability to whole assets at 93.10. It shows enduring liability to the whole principal at 110.28 and enduring liability to assets at 0.92 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 12.26 points at 1st support level, the second support level is making up to 11.47. But as of 1st resistance point, this stock is sitting at 13.70 and at 14.35 for 2nd resistance point.

Flexion Therapeutics Inc. [FLXN] reported its earnings at -$0.76 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.65/share signifying the difference of -0.11 and -16.90% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.95 calling estimates for -$1/share with the difference of 0.05 depicting the surprise of 5.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Flexion Therapeutics Inc. [NASDAQ:FLXN] is 6.60. Likewise, the Quick ratio is also the same, showing Cash ratio at 3.77. Now if looking for a valuation of this stock’s amount to sales ratio it’s 10.81.

Insider Stories

The most recent insider trade was by Stejbach Mark, Director, and it was the purchase of 2051.0 shares on May 26. Clayman Michael D., the President and CEO, completed a purchase of 10256.0 shares on May 26. On May 07, Arkowitz David, Chief Financial Officer, completed a sale of 2413.0 shares.